Exelixis (EXEL) Revenue Growth (1y) (2011 - 2026)
Exelixis (EXEL) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 96.43% |
| 10 | Exelixis | 14.48 Bn | 13.70 Bn | 590.86 Mn | 9.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 9.97% |
| Jan 2, 2026 | 5.63% |
| Oct 3, 2025 | 10.79% |
| Jul 4, 2025 | -10.82% |
| Apr 4, 2025 | 30.62% |
| Jan 3, 2025 | 18.16% |
| Sep 27, 2024 | 14.33% |
| Jun 28, 2024 | 35.61% |
| Mar 29, 2024 | 4.02% |
| Dec 29, 2023 | 13.15% |
| Sep 29, 2023 | 14.62% |
| Jun 30, 2023 | 12.02% |
| Mar 31, 2023 | 14.83% |
| Sep 30, 2022 | 25.37% |
| Jul 1, 2022 | 8.89% |
| Apr 1, 2022 | 31.73% |
| Oct 1, 2021 | 42.12% |
| Jul 2, 2021 | 48.44% |
| Apr 2, 2021 | 19.09% |
| Jan 1, 2021 | 12.38% |